#ESMO22: After day filled with investor, GSK appetite, SpringWorks brings out the data for cancer drug nearing FDA

On the cusp of asking the FDA to approve its cancer drug for progressing desmoid tumors, SpringWorks is out with a fuller picture of the …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ES­MO22: Af­ter day filled with in­vestor, GSK ap­petite, Spring­Works brings out the da­ta for can­cer drug near­ing FDA